Cargando…

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease

OBJECTIVE: Monitoring of patients with Cushing’s disease on cortisol-lowering drugs is usually performed with urinary free cortisol (UFC). Late-night salivary cortisol (LNSC) has an established role in screening for hypercortisolism and can help to detect the loss of cortisol circadian rhythm. Less...

Descripción completa

Detalles Bibliográficos
Autores principales:	Newell-Price, John, Pivonello, Rosario, Tabarin, Antoine, Fleseriu, Maria, Witek, Przemysław, Gadelha, Mônica R, Petersenn, Stephan, Tauchmanova, Libuse, Ravichandran, Shoba, Gupta, Pritam, Lacroix, André, Biller, Beverly M K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2019
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003692/ https://www.ncbi.nlm.nih.gov/pubmed/31804965 http://dx.doi.org/10.1530/EJE-19-0695

Ejemplares similares

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
por: Fleseriu, Maria, et al.
Publicado: (2019)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One!
por: Fleseriu, Maria
Publicado: (2020)

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

High variability in baseline urinary free cortisol values in patients with Cushing’s disease
por: Petersenn, S, et al.
Publicado: (2014)

Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Late-night salivary cortisol and cortisone should be the initial screening test for Cushing’s syndrome
por: Mohamed, Ramjan Sanas, et al.
Publicado: (2022)

Medical management of Cushing’s disease: what is the future?
por: Fleseriu, Maria, et al.
Publicado: (2012)

Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
por: Fleseriu, Maria, et al.
Publicado: (2022)

New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy
por: Fleseriu, Maria, et al.
Publicado: (2013)

MON-172 Comparison of a Late-night Salivary Cortisol Immunoassay and a Cortisol and Cortisone LCMS Assay in Patients with Cushing’s Disease
por: Kannankeril, Joshua, et al.
Publicado: (2020)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
por: Fleseriu, Maria, et al.
Publicado: (2022)

Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome
por: Kannankeril, Joshua, et al.
Publicado: (2020)

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess
por: Pivonello, Rosario, et al.
Publicado: (2020)

Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)
por: Fleseriu, Maria, et al.
Publicado: (2022)

Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study
por: Pivonello, Rosario, et al.
Publicado: (2021)

Levoketoconazole treatment in endogenous Cushing’s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes
por: Fleseriu, Maria, et al.
Publicado: (2022)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
por: Petersenn, S., et al.
Publicado: (2017)

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease
por: Fleseriu, Maria, et al.
Publicado: (2015)

Bedtime Salivary Cortisol as a Screening Test for Cushing Syndrome in Children
por: Ueland, Grethe Å, et al.
Publicado: (2021)

ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome
por: Newell-Price, John, et al.
Publicado: (2020)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

Cushing’s disease: adrenal steroidogenesis inhibitors
por: Pivonello, Rosario, et al.
Publicado: (2022)

MON-LB078 Desmopressin Stimulated Salivary Cortisol as a Suplementary Tool in the Diagnosis of Cushing's Syndrome
por: Firme, Ricardo
Publicado: (2019)

Neuropsychiatric disorders in Cushing's syndrome
por: Pivonello, Rosario, et al.
Publicado: (2015)

The dopaminergic control of Cushing’s syndrome
por: Pivonello, R., et al.
Publicado: (2022)

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
por: Manetti, Luca, et al.
Publicado: (2019)

SAT-443 Osilodrostat Has No Clinically Relevant Effect on the Pharmacokinetic (PK) Profile of a Monophasic Oral Contraceptive in Healthy Females Receiving Cortisol Replacement Therapy
por: Breitschaft, Astrid, et al.
Publicado: (2019)

Salivary Cortisone to Estimate Cortisol Exposure and Sampling Frequency Required Based on Serum Cortisol Measurements
por: Harrison, Robert F, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_smocgp8e0qfrnr8vvhjdsjoh91